Johnson & Johnson has an overall rating of 4.1 out of 5, based on over 16,627 reviews left anonymously by employees. 84% of employees would recommend working at Johnson & Johnson to a friend and 76% have a positive outlook for the business. This rating has been stable over the past 12 months.The company is a producer of medical devices and pharmaceuticals, and the owner of many well- known consumer brands (such as Band-Aid, Aveeno, Reach, Splenda, Tylenol, Zyrtec, etc.). The company has 128,700 employees worldwide, and total annual revenue exceeding $70 billion.Johnson & Johnson's stock does look cheap relative to other healthcare stocks, and this could still be a good long-term buy. But for the time being investors may be better off waiting for the issues relating to the talc lawsuits to be resolved before buying the stock.
Why is Johnson and Johnson so successful : Over the years, the company pushed further into the health and wellness industry by developing, innovating, and marketing new and improved products aimed at consumers. Johnson & Johnson's array of consumer goods isn't merely wide, but dominant.
What is Johnson and Johnson ranked
Johnson & Johnson has been named one of the World's Most Admired Companies in 2023 by Fortune Magazine and has ranked No. 1 in the Pharmaceutical Industry. Fortune collaborated with Korn Ferry to evaluate the performance and reputations of 645 companies across 27 countries.
Is Johnson & Johnson an industry leader : Founded in 1886 in New Brunswick, New Jersey, Johnson & Johnson is one of the largest pharmaceutical and medical technology companies in the world. In 2023, the company generated some 85 billion U.S. dollars of total revenue.
Johnson & Johnson acquired Pfizer's consumer healthcare business, expanding the company's capacity to meet rising global needs.
Johnson & Johnson
Drug
Indication
(+/-%)
Stelara
psoriasis, Crohns' disease, ulcerative colitis
19%
Darzalex
Multiple myeloma
44%
Imbruvica
oncology
6%
Invega
Sustenna schizophrenia
10%
Why is JNJ dropping
Johnson & Johnson's stock falls as profit beats but sales fall slightly short of estimates. Johnson & Johnson's stock was on pace for its lowest close since late 2020 on Tuesday, after the healthcare company posted better-than-expected profit for the first quarter but sales that fell slightly short of expectations.Is Johnson & Johnson stock a Buy, Sell or Hold Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 45 buy ratings, 32 hold ratings, and 1 sell ratings. What was the 52-week low for Johnson & Johnson stockA commitment to tackling the world's toughest health challenges has fueled Johnson & Johnson since its founding in 1886. And today the company is being recognized for this work, landing a spot on Fortune's World's Most Admired Companies list for the 22nd year in a row.
This article discusses the 2024 list of Fortune's Most Admired Companies, as well as how you can make your company a standout in your industry.
Apple.
Microsoft.
Amazon.
Berkshire Hathaway.
JPMorgan Chase.
Costco Wholesale.
Alphabet.
American Express.
What is the Johnson and Johnson controversy : In 2018, a Missouri court ordered Johnson & Johnson to pay nearly $4.7 billion to 22 women claiming asbestos in the company's talcum powder was linked to their cases of ovarian cancer.
What drugs do Johnson and Johnson make : Pharmaceutical therapies
Concerta.
Invega.
Ponvory.
Risperdal Consta.
Spravato.
Topamax.
Trevicta.
Xeplion.
What is J&J’s best selling product
Top revenue-producing drugs include: Stelara, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, Opsumit. Medical Device Sales – $23 billion. Top revenue-producing devices include: Hip implants, knee implants, spine implants, contact lenses and surgery products such as surgical mesh.
Overall, the performance of JNJ stock with respect to the index has been quite volatile. Returns for the stock were 9% in 2021, 3% in 2022, and -11% in 2023. In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 24% in 2023 — indicating that JNJ underperformed the S&P in 2021 and 2023.In 2018, a Missouri court ordered Johnson & Johnson to pay nearly $4.7 billion to 22 women claiming asbestos in the company's talcum powder was linked to their cases of ovarian cancer.
Where will JNJ stock be in 5 years : Long-Term Johnson & Johnson Stock Price Predictions
![Kladsko-5-malý-Karlův-Most[1]](https://www.einarstrayorchestra.com/wp-content/uploads/2024/06/Kladsko-5-maly-Karluv-Most1-1024x692-250x120.jpg)
![Stubai[1]](https://www.einarstrayorchestra.com/wp-content/uploads/2024/06/Stubai1-250x120.jpg)
Antwort Is Johnson and Johnson a good company? Weitere Antworten – Does Johnson and Johnson have a good reputation
Johnson & Johnson has an overall rating of 4.1 out of 5, based on over 16,627 reviews left anonymously by employees. 84% of employees would recommend working at Johnson & Johnson to a friend and 76% have a positive outlook for the business. This rating has been stable over the past 12 months.The company is a producer of medical devices and pharmaceuticals, and the owner of many well- known consumer brands (such as Band-Aid, Aveeno, Reach, Splenda, Tylenol, Zyrtec, etc.). The company has 128,700 employees worldwide, and total annual revenue exceeding $70 billion.Johnson & Johnson's stock does look cheap relative to other healthcare stocks, and this could still be a good long-term buy. But for the time being investors may be better off waiting for the issues relating to the talc lawsuits to be resolved before buying the stock.
Why is Johnson and Johnson so successful : Over the years, the company pushed further into the health and wellness industry by developing, innovating, and marketing new and improved products aimed at consumers. Johnson & Johnson's array of consumer goods isn't merely wide, but dominant.
What is Johnson and Johnson ranked
Johnson & Johnson has been named one of the World's Most Admired Companies in 2023 by Fortune Magazine and has ranked No. 1 in the Pharmaceutical Industry. Fortune collaborated with Korn Ferry to evaluate the performance and reputations of 645 companies across 27 countries.
Is Johnson & Johnson an industry leader : Founded in 1886 in New Brunswick, New Jersey, Johnson & Johnson is one of the largest pharmaceutical and medical technology companies in the world. In 2023, the company generated some 85 billion U.S. dollars of total revenue.
Johnson & Johnson acquired Pfizer's consumer healthcare business, expanding the company's capacity to meet rising global needs.
Johnson & Johnson
Why is JNJ dropping
Johnson & Johnson's stock falls as profit beats but sales fall slightly short of estimates. Johnson & Johnson's stock was on pace for its lowest close since late 2020 on Tuesday, after the healthcare company posted better-than-expected profit for the first quarter but sales that fell slightly short of expectations.Is Johnson & Johnson stock a Buy, Sell or Hold Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 45 buy ratings, 32 hold ratings, and 1 sell ratings. What was the 52-week low for Johnson & Johnson stockA commitment to tackling the world's toughest health challenges has fueled Johnson & Johnson since its founding in 1886. And today the company is being recognized for this work, landing a spot on Fortune's World's Most Admired Companies list for the 22nd year in a row.
This article discusses the 2024 list of Fortune's Most Admired Companies, as well as how you can make your company a standout in your industry.
What is the Johnson and Johnson controversy : In 2018, a Missouri court ordered Johnson & Johnson to pay nearly $4.7 billion to 22 women claiming asbestos in the company's talcum powder was linked to their cases of ovarian cancer.
What drugs do Johnson and Johnson make : Pharmaceutical therapies
What is J&J’s best selling product
Top revenue-producing drugs include: Stelara, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, Opsumit. Medical Device Sales – $23 billion. Top revenue-producing devices include: Hip implants, knee implants, spine implants, contact lenses and surgery products such as surgical mesh.
Overall, the performance of JNJ stock with respect to the index has been quite volatile. Returns for the stock were 9% in 2021, 3% in 2022, and -11% in 2023. In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 24% in 2023 — indicating that JNJ underperformed the S&P in 2021 and 2023.In 2018, a Missouri court ordered Johnson & Johnson to pay nearly $4.7 billion to 22 women claiming asbestos in the company's talcum powder was linked to their cases of ovarian cancer.
Where will JNJ stock be in 5 years : Long-Term Johnson & Johnson Stock Price Predictions